#United States #San Diego #Mitsubishi Tanabe #RADICAVA #ND0612

Mitsubishi Tanabe Pharma America to Present New Neurodegenerative Research Findings at AAN 2025 Annual Meeting

Mitsubishi Tanabe Pharma America, Inc. (MTPA) is set to feature prominently at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, taking place from April 5 to 9 in San Diego, California. The company has announced that it will present 11 studies highlighting significant advances in the field of neurodegenerative diseases, particularly focusing on Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS).

Key Highlights from the Presentations

MTPA's Vice President of Medical Affairs, Dr. Gustavo A. Suarez Zambrano, expressed enthusiasm about joining the scientific community at this vital meeting, emphasizing the importance of sharing insights from both clinical and real-world studies concerning PD and ALS. The presentations will include two posters focusing on Parkinson's disease and nine addressing ALS, showcasing a commitment to advancing knowledge in these challenging areas of healthcare.

Parkinson's Disease Insights

One of the notable highlights for Parkinson's disease is the investigational drug ND0612. The presentations will draw attention to important findings from the Phase 3 BouNDless trial, including an oral presentation on how a 24-hour treatment with ND0612 affects motor state transitions in patients throughout the day. Additionally, quality of life outcomes related to motor fluctuations will also be analyzed.

1. Impact of 24-hour Subcutaneous Levodopa/Carbidopa Infusion (ND0612): Dr. Rajesh Pahwa from the University of Kansas Medical Center will present findings focusing on motor function efficacy outcomes from the Phase 3 BouNDless Study during a Scientific Platform Session scheduled for April 9.
2. Quality of Life Analysis: Dr. Harini Sarva from New York Presbyterian Hospital will present a poster detailing quality of life results stemming from a randomized, active-controlled study related to ND0612 on the same day.

Advances in Amyotrophic Lateral Sclerosis (ALS)

The ALS presentations will delve into the effectiveness and safety of RADICAVA ORS® (edaravone), an established treatment for ALS. Key aspects will include:

• - Final Results from the MT-1186-A03 Extension Study: Dr. Alejandro Salah will provide insights from a long-term safety study of RADICAVA ORS, examining its effects over a 96-week period. This presentation is part of a Scientific Platform Session on April 8.
• - The MT-1186-A04 Extension Study: Dr. Stephen Apple will discuss additional findings on the ongoing evaluation of the drug over a 48-week period, shedding light on its continued efficacy and safety, comparing investigational daily dosing against the FDA-approved regimen.
• - Real-World Data Assessments: There will be multiple poster presentations assessing real-world treatment patterns in ALS, including how changes in telespirometry have been utilized to monitor patient progress in an at-home setting.

Broader Implications and Conclusions

The vital data being presented at the AAN meeting not only showcases Mitsubishi Tanabe's commitment to pioneering research in neurodegeneration but also aims to bridge the gap between clinical findings and everyday patient outcomes. The spotlight on ND0612 and RADICAVA ORS reveals a focused effort to provide innovative solutions for individuals living with conditions that profoundly affect their daily lives.

Overall, Mitsubishi Tanabe Pharma America’s participation in AAN 2025 promises to enhance the understanding and treatment strategies for Parkinson's and ALS, reaffirming their dedication to addressing crucial healthcare challenges. The research and outcomes presented are expected to be influential in shaping future therapeutic approaches in these complex disease areas.

As the AAN conference approaches, the scientific community eagerly awaits insights that may provide hope for better management and potential breakthroughs in the treatment of neurodegenerative diseases.